NCT03289962: A Study of RO7198457 (Personalized Cancer Vaccine [PCV] as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Primary central nervous system (CNS) malignancy, untreated CNS metastases, or active CNS metastases- see trial for details

Comments are closed.

Up ↑